Hyperdiploid myeloma cell as an indicator of poor prognosis and drug refractoriness.

Hata, H; Matsuzaki, H; Yoshida, M; Sonoki, T; Kuribayashi, N; Nagasaki, A; Kimura, T; Harada, N; Takatsuki, K

Hata, H; Matsuzaki, H; Yoshida, M; Sonoki, T; Kuribayashi, N; Nagasaki, A; Kimura, T; Harada, N; Takatsuki, K.

Affiliation

Hata H; Second Department of Internal Medicine, Kumamoto University School of Medicine, Japan.

Int J Hematol ; 66(2): 219-26, 1997 Aug.

Article in En | MEDLINE | ID: mdl-9277053

Subject(s)

Aneuploidy; Multiple Myeloma/pathology; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols/pharmacology; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Bone Marrow/pathology; Cell Nucleus/ultrastructure; DNA, Neoplasm/analysis; Drug Resistance, Neoplasm/genetics; Female; Humans; Male; Middle Aged; Multiple Myeloma/drug therapy; Multiple Myeloma/genetics; Multiple Myeloma/mortality; Pleural Effusion/pathology; Prognosis; Survival Rate; Treatment Outcome

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Aneuploidy / Multiple Myeloma Type of study: Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Int J Hematol Journal subject: HEMATOLOGIA Year: 1997 Document type: Article Affiliation country: Japan Country of publication: Japan

Search on Google

Add to My VHL

XML

PubMed Links